Hangzhou Kangji Weijing Medical Robotics Co., Ltd. has recently successfully closed a Series B+ financing round, raising over a hundred million yuan. This particular funding round saw exclusive investment from Guotai Junan Innovation Investment Co., Ltd., with strategic shareholder Kangji Medical also contributing additional capital. Gelu Capital played a pivotal role as the exclusive financial advisor in this deal.

The freshly raised capital will be strategically allocated to expedite the product commercialization journey. Additionally, it will fuel research and development endeavors, as well as facilitate the clinical registration process for the company's next - generation products.

The company's core team boasts a strong academic pedigree, with its members hailing from relevant laboratories at the prestigious Harbin Institute of Technology. Leveraging this expertise, they have constructed a comprehensive product matrix tailored to meet clinical needs. Through relentless efforts, the team has achieved multiple technological milestones in areas such as control systems, system performance, and surgical experience. Moreover, they have delved deep into the realm of embodied intelligence, pushing the boundaries of medical robotics.

The company's flagship product, a four - arm laparoscopic surgical robot, has reached a significant milestone. It obtained its registration certificate in April 2025 and has since commenced trial use in more than 10 top - tier hospitals across the country, marking a major step forward in the adoption of advanced surgical technologies.